Key Takeaways
- • SymBiosis Capital Management, LLC launched as a newly independent venture capital firm focused on biotherapeutics, according to a Business Wire release dated October 26, 2021.
- • The firm has significant long-term capital commitments supporting a portfolio of more than 20 investments, and it has been investing since 2019.
- • SymBiosis expects to deploy $5-$15 million per initial investment, scalable to over $30 million per investment across multiple financings.
- • The firm targets private companies with programs in, or about to enter, human trials, and acts as both lead and syndicate participant.
- • Managing Partner Chidozie Ugwumba leads a team that is recruiting for Analytics Platform Lead, Business Development Lead, General Counsel, and Operating Advisor roles.
Summary
SymBiosis Capital Management, LLC ("SymBiosis") announced its launch as a newly independent venture capital firm focused on advancing biotherapeutics innovations, according to a Business Wire release. The firm has been investing since 2019 and has received significant, long-term capital commitments to support its current portfolio of more than 20 investments and to fund future investments. The announcement did not disclose the size of the committed capital.
The firm is led by Managing Partner Chidozie Ugwumba, who previously was Managing Director, Direct Investments at WIT, LLC. The founding team includes Aleksei Cremo, Vice President, formerly an Associate focused on direct venture capital investments at WIT, LLC; Nick Smith, Investment Associate, formerly a Senior Analyst at WIT; and Molly Connor, Chief of Staff, formerly a Coordinator at WIT. The team is seeking candidates for Analytics Platform Lead, Business Development Lead, General Counsel, and Operating Advisor roles.
SymBiosis expects to initially deploy $5-$15 million per investment, with the ability to scale to over $30 million per investment across multiple financings. The firm invests across disease area, financing stage, and geography, with a focus on private companies with programs in, or about to enter, human trials. It will continue to serve as both a lead investor and a syndicate participant in financing rounds.
Mr. Ugwumba said the firm begins its new chapter at a time when innovation in biotechnology is accelerating, and he expects engineered biology to transform human life and define the twenty-first century. The firm is headquartered in Bentonville, Arkansas.
The firm is led by Managing Partner Chidozie Ugwumba, who previously was Managing Director, Direct Investments at WIT, LLC. The founding team includes Aleksei Cremo, Vice President, formerly an Associate focused on direct venture capital investments at WIT, LLC; Nick Smith, Investment Associate, formerly a Senior Analyst at WIT; and Molly Connor, Chief of Staff, formerly a Coordinator at WIT. The team is seeking candidates for Analytics Platform Lead, Business Development Lead, General Counsel, and Operating Advisor roles.
SymBiosis expects to initially deploy $5-$15 million per investment, with the ability to scale to over $30 million per investment across multiple financings. The firm invests across disease area, financing stage, and geography, with a focus on private companies with programs in, or about to enter, human trials. It will continue to serve as both a lead investor and a syndicate participant in financing rounds.
Mr. Ugwumba said the firm begins its new chapter at a time when innovation in biotechnology is accelerating, and he expects engineered biology to transform human life and define the twenty-first century. The firm is headquartered in Bentonville, Arkansas.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.